AACI: President-elect Biden has proven his unyielding commitment to defeating cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Karen E. Knudsen, MBA, PhD 
President, Association of American Cancer Institutes Enterprise director, Sidney Kimmel Cancer Center at Jefferson 

In a year of monumental health care and operational challenges for cancer centers, the Association of American Cancer Institutes marks with enthusiasm the electoral victory of a presidential candidate who has proven his unyielding commitment to defeating cancer.

AACI stands ready to work with President-elect Joe Biden, Vice President-elect Kamala Harris, the new administration, and Congress to continue our collective efforts against both cancer and the coronavirus pandemic.

Representing the 102 major cancer centers of North America, and dedicated to accelerating progress against cancer, AACI formed a strong bond with President-elect Biden during his leadership of President Barack Obama’s Cancer Moonshot initiative, launched in 2016.

On the first stop of a tour following a Cancer Moonshot Summit, in Washington, D.C., Biden, then vice president, visited Case Comprehensive Cancer Center, in Cleveland, meeting with the center’s director, Dr. Stan Gerson, who was AACI’s president-elect at the time. Overall, 40 AACI cancer centers hosted regional Cancer Moonshot summits in 25 states.

Following the Cleveland meeting, AACI submitted a white paper to the Moonshot office, signaling the AACI cancer centers’ readiness to deliver high-quality care across networks and improve the availability of carepaths, innovation, proper referrals, and clinical trials to a larger population of patients. The document was signed by all cancer center directors at the national summit and marked the first step in Dr. Gerson’s network care AACI Presidential Initiative.

At the request of the Moonshot Task Force, cancer centers submitted development projects for consideration as part of a Cancer Moonshot investment portfolio. A total of 224 proposals from 55 AACI cancer centers were shared with Greg Simon, executive director for both the Biden Cancer Initiative and the Cancer Moonshot Task Force. Mr. Simon was later a featured speaker at the 2016 AACI/CCAF Annual Meeting.

AACI looks forward to extending its key role in contributing to the federal government’s accelerated effort to eradicate cancer. As a consistent advocate for increased federal funding for cancer research, AACI this year asked Congress to ensure that additional funds be made available through the 21st Century Cures Act for the Beau Biden Cancer Moonshot.

AACI also looks forward to working with the new administration in the current AACI Presidential Initiative to leverage the strength of the AACI cancer centers to understand and mitigate cancer disparities [The Cancer Letter, Oct. 16, 2020].

Finally, we applaud president-elect Biden’s selection of Kamala Harris as the nation’s first woman and person of color to be vice president. Her rise to the highest level of government sets an example for cancer centers seeking diversity and inclusion in both institutional leadership and the wider oncology workforce [The Cancer Letter, Oct. 9, 2020].

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login